Tekla Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Tekla Capital Management's BMY Position: Q2 2023 in Review
Tekla Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 31% in Q2 2023, selling an estimated $13.8M and leaving 458,498 shares worth $29.3M. The position accounts for 1.15% of the portfolio, ranked #23.
Tekla Capital Management first reported a position in BMY in Q2 2014 and has held it in 33 quarters since. The position peaked at $62.5M in Q3 2022. 2,482 funds tracked by Wall St. Rank hold BMY as of Q2 2023.
- Tekla Capital Management held 458,498 shares of Bristol-Myers Squibb worth $29.3M as of Q2 2023.
- Tekla Capital Management sold 205,298 Bristol-Myers Squibb shares in Q2 2023, an estimated $13.8M.
- Bristol-Myers Squibb made up 1.15% of Tekla Capital Management's portfolio in Q2 2023, its #23 holding.
- Tekla Capital Management first reported a position in Bristol-Myers Squibb in Q2 2014 and has held it in 33 quarters since.
- Tekla Capital Management's Bristol-Myers Squibb position peaked at $62.5M in Q3 2022.
- 2,482 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.